Essential amino acid carrier with microenvironment redox response and lesion cell antioxidant treatment functions as well as preparation method and application of essential amino acid carrier

By designing a redox-sensitive multi-block polymer nanocarrier mPEG-GSH-PLys-PPhe, combining GSH modification and MXRA5 gene vector, the placenta targeting and toxicity problems in the prior art are solved, and efficient treatment of placental diseases is achieved. and low toxicity delivery significantly improves therapeutic effects.

CN118975983APending Publication Date: 2024-11-19THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411081861.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art cannot effectively target the placenta, making it difficult for the treatment of pregnancy diseases to stay in the placenta, which has potential toxicity to the mother and the fetus, and lacks targeting, affecting the efficacy.

Method used

A multi-block polymer nanocarrier mPEG-GSH-PLys-PPhe was designed to quickly release drugs in the ischemia-hypoxic microenvironment of the placenta through redox-sensitive chemical bonds, combining GSH modification and MXRA5 gene vector to achieve placental targets. Delivery and antioxidant therapy.

Benefits of technology

It has achieved efficient targeting and low toxicity of drugs in the placenta, reduced toxicity to the mother and fetus, improved the efficacy of treating oxidative stress diseases such as preeclampsia, and significantly reduced the impact of liver toxicity and renal function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975983A_ABST
    Figure CN118975983A_ABST
Patent Text Reader

Abstract

The invention discloses an essential amino acid carrier capable of delivering microenvironment redox response of treatment genes including MXRA5 and having a lesion cell antioxidant treatment function as well as a preparation method and application of the essential amino acid carrier. The carrier is a micelle formed by self-assembly of a multi-block polymer in water, the multi-block polymer is mPEG-GSH-PLys-PPhe, a hydrophilic shell of the multi-block polymer is mPEG-GSH, an inner core of the multi-block polymer is PLys-PPhe wrapping placenta disease treatment drugs or treatment genes such as MXRA5, and the shell and the inner core are connected through an amido bond. The mPEG-GSH-PLys-PPhe nano-carrier prepared through proper structural design and modification means not only has high-efficiency targeting property on placenta lesions, reduces toxicity to maternal bodies or fetuses, but also can respond to ROS microenvironments inside and outside cells of oxidative stress diseases, especially in the cells, plays an anti-oxidation role, and can be used for preparing the anti-oxidation placenta nano-carrier for treating the oxidative stress diseases in the maternal bodies or the fetuses of the maternal bodies or the fetuses of the maternal bodies or the fetuses of the maternal bodies. And a novel drug carrier system is provided for treating diseases related to oxidative stress in placenta such as preeclampsia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and nanomedicine, and specifically relates to an essential amino acid carrier with microenvironment redox response and diseased cell antioxidant therapeutic function, and a preparation method and application thereof. Background Art

[0002] The increased incidence of pregnancy diseases affects the health of the mother and the fetus, causing women of childbearing age and their families to be "terrified of pregnancy", and is one of the important medical factors affecting the birth rate. The placenta is the only channel connecting the mother and the fetus. The vast majority (90% or even more) of pregnancy diseases (gestational hypertension, diabetes, fetal maldevelopment, miscarriage) are related to basic pathological changes in the placenta. However, there are currently no specific drugs targeting pregnancy diseases. This is mainly because there are no clinical therapeutic targets for placental diseases, including preeclampsia. Even if the therapeutic target is extracted, the use of previous technologies cannot keep the drug in the expected therapeutic target-the placenta-to produce therapeutic effects. Because drugs that cannot be targeted for placental distribution have potential maternal / infant toxicity, they cannot be used.

[0003] In the placenta, the "fetal barrier" between maternal blood and fetal blood mainly performs the function of material exchange. Nutrition, drugs and even pathogens that enter the maternal blood can easily pass through the placental barrier. After a potentially toxic drug enters the placenta, as long as it cannot be effectively retained in the placenta, it is easy to enter the fetus, affecting its growth and development, and even causing malformations, stillbirths and miscarriages. The maternal uterine veins and the uterine artery blood supply characteristics have a very large amount of venous blood flowing out. After a potentially toxic drug enters the placenta, as long as it cannot be effectively retained in the placenta, it is also easy to flow back to the maternal circulation through the uterine veins, causing toxicity to the mother. Therefore, achieving targeted delivery of drugs in the placenta and their retention in the placenta are key technologies for the development of drugs for the treatment of placental diseases. The lack of a carrier that allows drugs to be retained in the placenta is the key problem that there are no targeted drugs for pregnancy diseases so far.

[0004] Various targeted delivery carriers, such as PEI, have obvious biological toxicity or are difficult to excrete and degrade, and cannot be used for placental and maternal and fetal diseases. Biological carriers (amino acids, cholesterol, bile acid) have high biological safety, are easily degraded after being absorbed by cells, and have high bioavailability. However, they are easily degraded during distribution, have poor stability, and have low drug loading efficiency.

[0005] Polylysine nanocarriers are also widely studied as gene delivery carriers in clinical practice because they have a high positive charge, can be completely degraded in the body, have a controllable structure and good monodispersity. However, compared with classic high-positive materials such as PEI, their gene loading efficiency is low. In order to improve the gene loading efficiency, high-generation dendritic polylysine nanoparticles inevitably have increased positive charge and enhanced cytotoxicity [Adv Drug Deliv Rev. 2020; 160: 199-211.]. Appropriate structural design and modification methods are needed to reduce the charge and toxicity of polylysine. In addition, the lack of targeting of the distribution of lysine carriers in the body may reduce the efficacy of drugs in the placenta and increase the potential toxicity of drugs outside the placenta. Therefore, it is necessary to improve its targeting of lesion distribution. Summary of the invention

[0006] In order to overcome the deficiencies and shortcomings of the prior art, the purpose of the present invention is to provide an essential amino acid carrier with microenvironment redox response and diseased cell antioxidant therapeutic function, and a preparation method and application thereof. The nanocarrier prepared by the present invention through appropriate structural design and modification means not only has high-efficiency targeting to placental lesions, reduces toxicity to the mother or fetus, but also can achieve response to the ROS microenvironment inside and outside the cells of oxidative stress diseases, especially the intracellular ROS microenvironment, and play an antioxidant role, thereby providing a new drug carrier system for the treatment of oxidative stress diseases such as preeclampsia.

[0007] The purpose of the present invention is achieved through the following technical solutions:

[0008] An essential amino acid carrier with microenvironment redox response and diseased cell antioxidant treatment function, the carrier is a micelle formed by self-assembly of a multi-block polymer in water, the multi-block polymer is mPEG-GSH-PLys-PPhe, its hydrophilic shell is mPEG-GSH, the core is PLys-PPhe encapsulating drugs or therapeutic genes, and the shell and the core are connected by an amide bond.

[0009] The present invention designs a drug carrier for microenvironment-sensitive delivery based on the characteristics of the placental lesion microenvironment, which is an effective means to achieve the treatment of placental diseases. The main function of the placenta is to supply blood and oxygen. In diseases such as preeclampsia, the lesions of the placenta are mainly manifested as ischemia and hypoxia, as well as oxidative stress after ischemia and hypoxia. Therefore, oxidative stress is an important feature of the diseased placental microenvironment and an important target for achieving targeted delivery in the placental microenvironment. Based on the unique redox microenvironment of the diseased placenta, the redox-sensitive drug delivery system can decompose the redox-sensitive chemical bonds on the outer shell, resulting in the rapid release of the encapsulated drug in the lesion microenvironment, showing good placental targeting and low toxicity.

[0010] Glutathione (GSH) is a key tripeptide composed of glutamic acid, cysteine ​​and glycine produced in the cytoplasm, with a molecular formula of C 10 H 17 O6SN3, in which the main group that plays a role is the reducing group thiol (-SH). GSH is the main reducing agent in the body and is considered to be the main thiol-disulfide redox buffer system of the cell. This makes GSH a redox reaction trigger in drug delivery. Redox-sensitive targeted nano drug delivery systems rely on redox-sensitive chemical bonds to play a role. These drug delivery systems are modified by GSH, and after reaching the redox lesion site, the GSH chemical bonds break due to the redox potential difference and play a reducing role, which can achieve accurate drug release and delivery to the lesion. Therefore, the present invention uses GSH to modify the shell of this group of positively charged gene carriers, so that it can obtain the ischemic hypoxia oxidative stress placental microenvironment delivery effect.

[0011] The design of placental drugs must take into account the low toxicity of the drug delivery kernel. Only a low toxic kernel can ensure the low toxicity and low teratogenicity of the drug to the fetus. Therefore, the present invention selects "lysine" in the "essential amino acids" that the fetus itself cannot synthesize and originally needs to be absorbed from the outside as the basic component of the drug kernel, ensuring that it does not produce obvious toxicity after being absorbed and degraded by the fetus, and even participates in the normal amino acid metabolism of the fetus. Polylysine nanocarriers can be completely degraded in vivo due to their high positive charge, controllable structure and good monodispersity, but lysine carriers lack targeting in vivo distribution, and cannot ensure the release and efficacy of drugs in the local placenta. The present invention adopts a GSH-modified placenta targeted delivery shell to enhance the placenta targeted distribution performance of the polylysine drug kernel.

[0012] The drug or therapeutic gene loaded in the vector core is the key to determining the therapeutic effect of nanomedicine after achieving placental distribution. The present invention selects the gene matrix remodeling associated protein 5 (Matrix Remodelling Associated Protein 5, MXRA5) that is lowly expressed in the placenta of preeclampsia as a therapeutic gene. MXRA5 is a secretory glycoprotein that contains 7 leucine-rich repeats and 12 perlecan-related immunoglobulin-like C2-type domains. It has been studied that it is predicted as a possible diagnostic and therapeutic target for preeclampsia in the sequencing and proteomics data of preeclampsia placenta in multiple centers. The present invention combines its overexpression vector in the drug core, and achieves the therapeutic effect of preeclampsia after achieving targeted distribution of the placenta, effective release of the microenvironment and effective transfection of cells.

[0013] The structural formula of the multi-block polymer of the present invention is:

[0014]

[0015] Among them, x=45-80, y=40-60, z=20-30.

[0016] The average particle size of the carrier of the present invention is 80-120nm.

[0017] The vector of the present invention can encapsulate drugs or therapeutic genes in polylysine PLys-PPhe with high positive charge properties. The therapeutic gene is a gene that plays an antioxidant role in cells. Preferably, the therapeutic gene is MXRA5.

[0018] The present invention also provides a method for preparing an essential amino acid carrier having microenvironment redox response and diseased cell antioxidant therapeutic function, comprising the following steps:

[0019] (1) Synthesis of mPEG-ss-GSH:

[0020] The monomethoxy-polyethylene glycol-thiol mPEG-SH was oxidized with glutathione in water at 20-25°C for 12-24 hours, and then dialyzed to obtain mPEG-ss-GSH;

[0021] (2) Synthesis of mPEG-GSH-PZLL:

[0022] Dissolve N6-benzyloxycarbonyllysine-L-carbonyl anhydride Lys-NCA and mPEG-ss-GSH obtained in step (1) in DMF, stir and react in an oil bath at 30-35° C. for 48-72 hours. After the reaction is completed, precipitate the reactants with excess ether to obtain mPEG-GSH-PZLL;

[0023] (3) Synthesis of mPEG-GSH-PZLL-PPhe:

[0024] The mPEG-GSH-PZLL and phenylalanine N-carbonyl carboxylic anhydride Phe-NCA synthesized in step (2) are dissolved in DMF, and stirred in an oil bath at 30-35° C. for 24-48 hours. After the reaction is completed, the reactants are precipitated with excess ether to obtain mPEG-GSH-PZLL-PPhe;

[0025] (4) Deprotection of mPEG-GSH-PZLL-PPhe

[0026] The mPEG-GSH-PZLL-PPhe obtained in step (3) is dissolved in trifluoroacetic acid, and hydrogen bromide gas is introduced, and the reaction is bubbling for 20-40 minutes, and the reaction is continued by stirring in an ice bath for 10-15 hours. The reactant is precipitated with excess ether to obtain deprotected mPEG-GSH-PZLL-PPhe;

[0027] (5) Preparation of Nanocarriers:

[0028] The deprotected mPEG-GSH-PLys-PPhe is dissolved in an aqueous solution, and then the nanoparticles are dispersed under ultrasound to obtain an mPEG-GSH-PLys-PPhe nanoparticle solution; the diluted solution of the drug or therapeutic gene is mixed with the mPEG-GSH-PLys-PPhe nanoparticle solution, blown to mix evenly, allowed to stand, and then dialyzed to obtain an essential amino acid carrier with microenvironment redox response and antioxidant therapeutic function of diseased cells.

[0029] Preferably, in step (1), the molar ratio of mPEG-SH to glutathione is 1:1; and the molecular cutoff of the dialysis bag used for dialysis is 0.5-1 kDa.

[0030] Preferably, in step (2), the molar ratio of the N6-benzyloxycarbonyllysine-L-carbonyl anhydride Lys-NCA to mPEG-ss-GSH is 40:1-60:1.

[0031] Preferably, in step (3), the molar ratio of the phenylalanine N-carbonyl carboxylic anhydride Phe-NCA to mPEG-GSH-PZLL is 20:1-30:1.

[0032] Preferably, in step (5), after removing the chloroform, the solution is filtered with an aqueous filter having a pore size of 0.4-0.6 μm to remove large aggregates, and then dialyzed in pure water with a dialysis bag having a molecular cutoff of 5-14 kDa to remove polymers that have not formed particles. Finally, the mPEG-GSH-PLys-PPhe nanoparticle solution is concentrated with an ultrafiltration tube having a molecular cutoff of 100-200 kDa, washed with pure water, and filtered through an aqueous filter having a pore size of 0.1-0.22 μm to obtain the mPEG-GSH-PLys-PPhe nanoparticle solution.

[0033] The present invention also provides the use of the essential amino acid carrier having the above-mentioned microenvironment redox response and diseased cell antioxidant therapeutic function in the preparation of drugs for treating placental oxidative stress-related diseases such as preeclampsia.

[0034] Compared with the prior art, the present invention has the following excellent effects:

[0035] The essential amino acid carrier with microenvironment redox response and diseased cell antioxidant therapeutic function provided by the present invention uses strong positive charge PLys-PPhe as the core to ensure the gene loading efficiency; negative charge polyethylene glycol-glutathione mPEG-GSH is used as the shell for surface modification, which can shield the strong positive charge of PLys-PPhe and reduce toxicity. In terms of improving the targeting of lesions, the negative charge shell is used to shield the positive charge of the inner core, and in the blood circulation process before entering the lesion, the positive charge is avoided to stimulate the reticuloendothelial system mainly composed of the liver, and it is not easy to be recognized, intercepted and engulfed by the reticuloendothelial system mainly composed of the liver, so that the drug reaches the uterus with high efficiency, and it is easy to enter the placenta after reaching the uterus. In terms of ROS response, the glutathione GSH in the shell after the nanocarrier enters the lesion can achieve the response to the ROS microenvironment inside and outside the cells of oxidative stress diseases, especially the intracellular ROS, and play an antioxidant role. Part of the GSH that undergoes antioxidant reaction reduces the stability of the outer shell, promotes the dissociation of the outer shell and the positive exposure of the inner core containing the drug carrier, and even releases part of the inner core, producing an efficient distribution effect similar to lesion targeting, reducing toxicity to the mother or fetus, and providing a new drug carrier system for the treatment of oxidative stress diseases such as preeclampsia. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The synthetic route of the multiblock polymer mPEG-GSH-PLys-PPhe is shown;

[0037] Figure 2 The transmission electron microscopy image of the mPEG-GSH-PLys-PPhe nanocarrier prepared in Example;

[0038] Figure 3 Schematic diagram of the structure of the mPEG-GSH-PLys-PPhe nanocarrier prepared in the example. DETAILED DESCRIPTION

[0039] The present invention is further described below by means of specific implementation methods. The following examples are specific implementation methods of the present invention, but the implementation methods of the present invention are not limited to the following examples.

[0040] The sources of the raw materials used in the embodiments of the present invention are shown in Table 1 below:

[0041] Table 1

[0042]

[0043] Example 1: Preparation of essential amino acid carriers with microenvironment redox response and antioxidant therapeutic function for diseased cells The synthetic route of the multi-block polymer mPEG-GSH-PLys-PPhe is shown in Figure 1 The specific steps are as follows:

[0044] (1) Synthesis of polyethylene glycol-disulfide-glutathione (mPEG-ss-GSH)

[0045] The mPEG-ss-GSH polymer was obtained by oxidation reaction of the active thiol of mPEG-SH with the thiol on glutathione GSH. The specific operation is as follows: mPEG-SH (2g, 1mmol) was weighed and stirred with glutathione (0.307g, 1mmol) in a 100mL round-bottom flask containing 20mL of aqueous solution, and reacted at 23°C for 18h. After the reaction, the unreacted GSH was removed by dialysis in pure water with a dialysis bag (molecular cutoff: 0.5kDa) for 1d, and the lyophilized product was obtained as a white powder, namely mPEG-ss-GSH (2.3g).

[0046] (2) Synthesis of polyethylene glycol-glutathione-poly (N-benzyloxycarbonyl lysine) (mPEG-GSH-PZLL)

[0047] mPEG-GSH-PZLL was synthesized by ring-opening polymerization. mPEG-GSH-NH2 was used as an initiator to initiate the ring-opening polymerization of N6-benzyloxycarbonyllysine-L-carbonyl anhydride (Lys-NCA) to obtain mPEG-GSH-PZLL. The specific operation of synthesizing mPEG-GSH-PZLL is as follows: 1.53g of Lys-NCA (5mmol) was weighed and placed in a Shrek bottle completely dried in an oven, ventilated three times with nitrogen, sealed and added with a syringe 20mL DMF, stirred and dissolved at 35℃, and then 5mL of mPEG-ss-GSH (0.23g, 0.1mmol) DMF solution prepared above was added, sealed and isolated from air under nitrogen environment, and stirred in an oil bath at 35℃ for 72h. After the reaction was completed, the reactant was precipitated with excess ether to obtain transparent and viscous mPEG-GSH-PZLL, which was redissolved in chloroform and precipitated with excess ether to obtain a white solid. Pure mPEG-GSH-PZLL powder (1.75 g) with terminal amino group was obtained by vacuum drying at 40°C for 24 h and stored at 4°C for future use.

[0048] (3) Synthesis of polyethylene glycol-glutathione-poly (N-benzyloxycarbonyllysine)-polyphenylalanine (mPEG-GSH-PZLL-PPhe)

[0049] Using terminal amino mPEG-GSH-PZLL powder as an initiator, phenylalanine N-carbonyl carboxylic anhydride (Phe-NCA) was induced to form polyethylene glycol-glutathione-poly (N-benzyloxycarbonyllysine)-polyphenylalanine (mPEG-GSH-PZLL-PPhe). The specific operation is as follows: 1.75g ​​of the above-synthesized mPEG-GSH-PZLL product and Phe-NCA (0.573g, 3mmol) were weighed and added into a Shrek bottle completely dried in an oven, ventilated with nitrogen three times, sealed and added with 25mL DMF (2wt%) by syringe, stirred in an oil bath at 35°C for 24h, and after the reaction was completed, the reactant was precipitated with excess ether to obtain a transparent and viscous white solid of mPEG-GSH-PZLL-PPhe. Pure mPEG-GSH-PZLL-PPhe powder (2.3 g) with terminal amino group was obtained by vacuum drying at 40°C for 24 h and stored at 4°C for future use.

[0050] (4) Deprotection of mPEG-GSH-PZLL-PPhe

[0051] mPEG-GSH-PZLL-PPhe was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced and bubbled for 30 min. The reaction was continued in an ice bath with stirring for 12 h, and then precipitated with excess ether to obtain the deprotected product. The deprotected polyethylene glycol-glutathione-polylysine-polyphenylalanine (mPEG-GSH-PLys-PPhe) was obtained by vacuum drying at 40 °C for 24 h. (5) Preparation of MXRA5 plasmid composite nanocarrier

[0052] Positively charged mPEG-GSH-PLys-PPhe nanoparticles and negatively charged MXRA5 plasmids can form nanocomplexes through electrostatic interaction. The specific operation is as follows: 500 μg of MXRA5 plasmid was diluted with PBS to a final volume of 1.5 mL and oscillated evenly. 20 mg of mPEG-GSH-PLys-PPhe was dissolved in 5 mL of PBS solution, and then the diluted solution of MXRA5 plasmid was added dropwise to the PBS solution (pH 7.4) of the nanocarrier at a rate of 0.5 mL / min under ultrasound. After the ultrasound was finished, the mixture was blown and allowed to stand for 30 minutes, and filtered with an aqueous filter head (pore size: 0.45 μm) to remove large aggregates. Subsequently, the solution was placed in a dialysis bag (molecular cutoff: 14 kDa) and dialyzed for 24 h to remove unreacted plasmids. After washing with PBS (pH 7.4), it was filtered through an aqueous filter (pore size: 0.22 μm) to obtain a uniform MXRA5 plasmid-complexed microenvironment redox response and essential amino acid carrier for antioxidant treatment of diseased cells (mPEG-GSH-PLys-PPhe nanocarrier) with an average particle size of 102.3 nm.

[0053] The morphological characteristics of the obtained nanocarriers were observed under a transmission electron microscope (TEM). The obtained nanocarrier solution (10 μL, 1 mg / mL) was dripped onto a 200-mesh pure carbon film copper grid, evaporated and dried at room temperature, and then 10 μL of a 1% mass fraction uranyl acetate solution was added to the copper grid, and dried with filter paper after 1 minute, and placed in a desiccator to dry overnight (room temperature), and its morphology was observed under TEM. Figure 2 The transmission electron micrograph of the prepared mPEG-GSH-PLys-PPhe nanocarrier is shown in FIG. It can be clearly seen from the circular structure with a diameter of about 100 nm in the figure that the nanocarrier prepared by the present invention is a micelle structure, which is formed by self-assembly of the amphiphilic polymer mPEG-GSH-PLys-PPhe.

[0054] Figure 3 Schematic diagram of the structure of the prepared mPEG-GSH-PLys-PPhe nanocarrier, the hydrophilic shell is mPEG-GSH, and the core is PLys-PPhe encapsulating drugs or therapeutic genes.

[0055] Embodiment 2:

[0056] In step (2), the amount of Lys-NCA added was 1.865 g, and in step (3), the amount of Phe-NCA added was 0.657 g. The rest was the same as in Example 1. The average particle size of the prepared nanocarrier was 118.9 nm.

[0057] Embodiment 3:

[0058] In step (2), the amount of Lys-NCA added was 1.227 g, and in step (3), the amount of Phe-NCA added was 0.488 g. The rest was the same as in Example 1. The average particle size of the prepared nanocarrier was 81.7 nm.

[0059] Comparative Example 1: Preparation of mPEG-PLys-PPhe nanocarrier

[0060] Using PZLL with terminal amino group as initiator, ring-opening polymerization of phenylalanine N-carbonylcarboxylic anhydride (Phe-NCA) was initiated to obtain polyethylene glycol-glutathione-poly (N-benzyloxycarbonyllysine)-polyphenylalanine (mPEG-PZLL-PPhe), followed by a deprotection step to obtain mPEG-PLys-PPhe.

[0061] The specific operations are as follows:

[0062] mPEG-PZLL was synthesized by ring-opening polymerization. mPEG-NH2 was used as an initiator to initiate the ring-opening polymerization of N6-benzyloxycarbonyllysine-L-carbonyl anhydride (Lys-NCA) to obtain mPEG-PZLL. The specific operation of synthesizing mPEG-PZLL is as follows: 1.53g of Lys-NCA (5mmol) was weighed and placed in a Shrek bottle completely dried in an oven, ventilated three times with nitrogen, sealed and added with a syringe 20mL DMF, stirred and dissolved at 35℃, and then 5mL of mPEG-NH2 (0.23g, 0.1mmol) DMF solution prepared above was added, sealed and isolated from air under nitrogen environment, and stirred in an oil bath at 35℃ for 72h. After the reaction was completed, the reactant was precipitated with excess ether to obtain transparent and viscous mPEG-PZLL, which was redissolved in chloroform and precipitated with excess ether to obtain a white solid. The pure amino-terminated mPEG-PZLL powder (1.75 g) was obtained by vacuum drying at 40°C for 24 h.

[0063] Weigh 1.75 g (0.1 mmol) of the mPEG-PZLL product synthesized above and Phe-NCA (0.573 g, 3 mmol) and add them into a Shrek bottle that has been completely dried in an oven. Refrigerate with nitrogen three times, seal the bottle, add 25 mL of DMF (2 wt %) with a syringe, and stir the reaction in an oil bath at 35 °C for 24 h. After the reaction is completed, the reactant is precipitated with excess ether to obtain a white product, mPEG-PZLL-PPhe.

[0064] mPEG-PZLL-PPhe was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced, and the reaction was bubbling for 30 minutes. The reaction was continued for 12 hours under ice bath stirring, and then precipitated with excess ether to obtain the deprotected product. The deprotected polyethylene glycol-polylysine-polyphenylalanine (mPEG-PLys-PPhe) was obtained by vacuum drying at 40°C for 24 hours.

[0065] Positively charged mPEG-PZLL-PPhe nanoparticles and negatively charged MXRA5 plasmids can form nanocomplexes through electrostatic interaction. The specific operation is as follows: 500 μg of MXRA5 plasmid was diluted with PBS to a final volume of 1.5 mL and oscillated evenly. 20 mg of mPEG-PZLL-PPhe was dissolved in 5 mL of PBS solution, and then the diluted solution of MXRA5 plasmid was added dropwise to the PBS solution (pH 7.4) of the nanocarrier at a rate of 0.5 mL / min under ultrasound. After the ultrasound ended, the mixture was blown and allowed to stand for 30 minutes, and filtered with an aqueous filter head (pore size: 0.45 μm) to remove large aggregates. Subsequently, the solution was placed in a dialysis bag (molecular cutoff: 14 kDa) and dialyzed for 24 h to remove unreacted plasmids. After washing with PBS (pH 7.4), it was filtered through an aqueous filter (pore size: 0.22 μm) to obtain uniform MXRA5 plasmid-complexed mPEG-PZLL-PPhe nanocarriers with an average particle size of 107.6 nm.

[0066] Comparative Example 2: Preparation of PLys-PPhe Nanocarrier

[0067] Polylysine-polyphenylalanine (PLys-PPhe) was synthesized by two-step ring-opening polymerization. First, cyclohexylamine was used as an initiator to initiate the ring-opening polymerization of N6-benzyloxycarbonyllysine-L-carbonyl anhydride (Lys-NCA) to obtain poly(N-benzyloxycarbonyllysine) (PZLL). Subsequently, the benzyloxycarbonyl protection of lysine was removed to obtain a polylysine-polyphenylalanine (PLys-PPhe) diblock copolymer. The specific operation is as follows: 2.040g of Lys-NCA (10mmol) was weighed and placed in a Shrek bottle that was completely dried in an oven, ventilated three times with nitrogen, sealed and added with a syringe 20mL of DMF, stirred and dissolved at 35℃, and then 5mL of cyclohexylamine (10mg, 0.1mmol) in DMF solution was added, sealed and isolated from the air under a nitrogen environment, and stirred in an oil bath at 35℃ for 72h. After the reaction is completed, the reactant is precipitated with excess ether to obtain transparent viscous PZLL, which is redissolved in chloroform and precipitated with excess ether to obtain a white solid. The pure terminal amino-group PZLL powder is obtained by vacuum drying at 40°C for 24 hours and stored at 4°C for later use.

[0068] Using PZLL with terminal amino group as initiator, ring-opening polymerization of phenylalanine N-carbonyl carboxylic anhydride (Phe-NCA) was initiated to obtain poly(N-benzyloxycarbonyllysine)-polyphenylalanine (PZLL-PPhe). The specific operation is as follows: 1.5g of the synthesized PZLL product and Phe-NCA (0.783g, 5mmol) were weighed and added into a Shrek bottle completely dried in an oven, ventilated with nitrogen three times, sealed and added with 25mL DMF (2wt%) by syringe, stirred in an oil bath at 35℃ for 24h, and after the reaction was completed, the reactant was precipitated with excess ether to obtain a white product PZLL-PPhe.

[0069] PZLL-PPhe was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced, and the reaction was bubbling for 30 min. The reaction was continued in an ice bath with stirring for 12 h, and then precipitated with excess ether to obtain the deprotected product. The deprotected PLys-PPhe was obtained by vacuum drying at 40 °C for 24 h.

[0070] Positively charged PLys-PPhe nanoparticles and negatively charged MXRA5 plasmids can form nanocomplexes by electrostatic interaction. The specific operation is as follows: 500 μg of MXRA5 plasmid was diluted with PBS to a final volume of 1.5 mL and shaken evenly. 18 mg of PLys-PPhe was dissolved in 5 mL of PBS solution, and then the diluted solution of MXRA5 plasmid was added dropwise to the PBS solution (pH 7.4) of the nanocarrier at a rate of 0.5 mL / min under ultrasound. After the ultrasound was finished, the solution was blown and allowed to stand for 30 minutes, and filtered with an aqueous filter head (pore size: 0.45 μm) to remove large aggregates. Subsequently, the solution was placed in a dialysis bag (molecular retention: 14 kDa), dialyzed for 24 hours to remove unreacted plasmids, washed with PBS (pH 7.4), and filtered through an aqueous filter head (pore size: 0.22 μm) to obtain uniform MXRA5 plasmid-complexed PLys-PPhe nanocarriers with an average particle size of 160.7 nm.

[0071] Comparative Example 3:

[0072] In step (1), the amount of mPEG is 0.400 g, in step (2), the amount of Lys-NCA is 2.040 g, and in step (3), the amount of Phe-NCA is 1.146 g.

[0073] The rest was the same as in Example 1, and the average particle size of the prepared nanocarrier was 200.2 nm.

[0074] Comparative Example 4:

[0075] In step (1), the amount of mPEG is 0.100 g, in step (2), the amount of Lys-NCA is 1.020 g, and in step (3), the amount of Phe-NCA is 0.382 g.

[0076] The rest was the same as in Example 1, and the average particle size of the prepared nanocarrier was 51.3 nm.

[0077] Application example: Functional evaluation experiment

[0078] 1. Near-infrared in vivo fluorescence (NIRF) molecular imaging experiments to evaluate the placenta-specific delivery function of drugs

[0079] Model building:

[0080] 8-week-old SPF-grade C57BL / 6 mice (purchased from Guangdong Medical Experimental Animal Center) were mated with male mice in a 2:1 ratio during estrus. The vaginal secretion smears of female mice were stained with Papanicolaou on the second day. The specimens with positive vaginal sperm were observed under an optical microscope and diagnosed as pregnancy, which was marked as pregnancy day 0 (D0). Pregnant mice were fed with 2 mg / mL nitroso-L-arginine methyl ester dissolved in sterile water to establish the preeclampsia / gestational hypertension model, and pregnant mice fed with an equal amount of double distilled water served as the normal control group.

[0081] NIRF imaging detects the placental distribution of drugs:

[0082] A molecular contrast agent (near-infrared dye CY7) was used for carrier staining and tracing. On the 11th day, the preeclampsia model animals were anesthetized with chloral hydrate, and the in vivo distribution of nanomedicines containing near-infrared fluorescent dyes was observed before (0h) and 2 hours (2h) after drug injection. The dosage of nanomedicines (Examples 1-3 and Comparative Examples 1-4) injected into the tail vein was: (therapeutic dose 12.5μg nucleic acid equivalent drug, or an equal volume of PBS); C57BL / 6 mice were imaged in vivo using the In vivo FX in vivo fluorescence scanner. The relative increase ratio of the signal in the placenta region (uterine region in the lower abdomen of the mouse) or the liver region was calculated 2h after drug injection (RSI (Relative Signal Intensity) % = R2h / R0h), and the results are shown in Table 2.

[0083] Table 2 Results of placenta-specific delivery function evaluation

[0084]

[0085] From the above results, it can be seen that the positive charge of the PLys-PPhe carrier kernel in Examples 1-3 is shielded by the mPEG-GSH shell, and in the blood circulation process before entering the lesion, the positive electricity is avoided to stimulate the liver-based reticuloendothelial system. The particle size of these drug carriers is within 80-120nm, which is not easily recognized, intercepted and engulfed by the liver-based reticuloendothelial system, and the liver is less retained; the particle size is smaller than the uterine spiral artery new capillary endothelial space that supplies blood to the placenta, and it is easy to enter the placenta after reaching the uterus, and the drug concentration in the placenta is relatively high. The molecular contrast agent compounded by the drug carrier is distributed with the drug, and a significant aggregation imaging signal is produced in the placenta.

[0086] In comparative example 1, the shell does not have GSH that can react with ROS in the placental lesion. After the nanocarrier enters the lesion, the shell cannot undergo obvious shell dissociation and release of the drug carrier core. The drug core that cannot be released flows out of the placenta with venous blood, and is rarely retained in the placental lesion. The molecular contrast agent of the drug complex is distributed with the drug, and the less aggregation in the placenta leads to a significantly reduced imaging signal compared with the embodiment, and the more aggregation in the liver leads to a significantly higher liver RSI imaging signal.

[0087] Comparative Example 2 lacks a shell that can cover up the strong positive charge of the inner core. In the blood circulation process before entering the lesion, the obvious positive charge on the surface of the inner core of the drug PLys-PPhe carrier stimulates the reticuloendothelial system mainly in the liver. Furthermore, the drug is significantly intercepted and engulfed by the reticuloendothelial system, the blood drug concentration is reduced, and very little drug enters the placenta. The molecular contrast agent of the drug complex is distributed with the drug, and the aggregation in the placenta is very small, resulting in a significant reduction in the imaging signal compared with the embodiment, and the aggregation in the liver is reduced, resulting in a significantly higher liver RSI imaging signal.

[0088] The nanocarrier particle size of Comparative Example 3 is too large, and it is easy to be recognized, intercepted and engulfed by the reticuloendothelial system mainly composed of the liver, resulting in a high drug concentration in the liver, and a significantly reduced blood drug concentration during the in vivo distribution process. In addition, its particle size is larger than the uterine spiral artery new capillary endothelial space that supplies blood to the placenta. Even if it reaches the uterus, the rate of entering the placenta is extremely low, and the drug concentration in the placenta is low. The molecular contrast agent of the drug complex is distributed with the drug, and the less aggregation in the placenta leads to a significantly reduced imaging signal compared with the embodiment, and the more aggregation in the liver leads to a significantly higher liver RSI imaging signal.

[0089] The nanocarrier particle size of Comparative Example 4 is too small, and it is not easy to be recognized, intercepted and engulfed by the reticuloendothelial system mainly composed of the liver. The liver is less retained, the drug concentration is low, and the blood drug concentration is not significantly reduced during the distribution process. However, its particle size is much smaller than the capillary endothelial gap between the placenta and the uterine vein. Even if it enters the placenta, it enters the uterine vein with the blood flow and is discharged from the placenta. The drug concentration in the placenta is low. The molecular contrast agent of the drug compound is distributed with the drug, and the less aggregation in the placenta leads to a significant reduction in the imaging signal compared with the embodiment, and the less aggregation in the liver leads to a significantly lower liver RSI imaging signal.

[0090] 2. Establishing an animal model of preeclampsia to evaluate the therapeutic effect

[0091] 12.5 μg nucleic acid equivalent drug or an equal volume of PBS was injected on D3, D6, D9, D12, and D15, and a series of tests were performed on D17. The test results are shown in Table 3:

[0092] Blood pressure test: Use the BP-2000 blood pressure analysis system to non-invasively measure the systolic blood pressure (SBP) of pregnant mice using the tail cuff method. Maintain the room temperature at 26 degrees Celsius, set channel 1 to 1V (1V is equivalent to 300mmHg), and channel 2 to SmV. Fix the mouse in a cage, place the mouse's tail in a 17mm tail cuff, and make sure the bottom of the tail contacts the sensor. When the pregnant mouse is in a quiet state, continuously apply pressure and measure 10 times, with an interval of 1s each time, take the average value and keep a record;

[0093] Placenta and fetus examination: Placenta tissue: Pregnant mice were killed, the abdominal cavity was opened, the uterus was dissected, and the fetuses and placenta were taken out in turn, and the number of surviving fetuses was recorded. The fetal membrane and umbilical cord on the placenta were removed, and the umbilical cord at the fetal end was cut off along the root of the umbilical cord. The placenta and fetus were placed on sterile gauze to absorb the surface amniotic fluid, and the fetus was weighed on an analytical balance. The cut placenta tissue was placed in liquid nitrogen and stored at -80℃.

[0094] Table 3 Evaluation of therapeutic effects in animal models of preeclampsia

[0095]

[0096] From the above results, it can be seen that in Examples 1-3, the GSH in the outer shell reacts with the ROS in the lesion after the drug carrier enters the lesion, playing a partial extracellular antioxidant role. Part of the GSH that undergoes antioxidant reaction reduces the stability of the outer shell, promotes the dissociation of the outer shell and the exposure of the positive charge of the inner core containing the drug carrier, and even releases part of the inner core, producing an effect similar to lesion targeting. The drug carrier with increased overall surface positive charge is easily endocytosed by the diseased cells in the placenta. After endocytosis, the residual GSH in the outer shell is in the cell and can also play an antioxidant function. Antioxidant treatment MXRA5 plasmid and residual GSH in the outer shell enter the diseased cells with the distribution of drugs, and play an antioxidant role in the cells. Compared with the untreated disease group model, blood pressure dropped significantly to approach the normal control group; fetal weight increased significantly to approach the normal control group; the number of litters per litter increased significantly to approach the normal control group.

[0097] In Comparative Example 1, the shell does not have GSH that can react with ROS in the placental lesions. After entering the lesions, the shell cannot play an extracellular antioxidant role, and there is no obvious shell dissociation and release of the core containing the drug carrier. The drug core that cannot be released flows out of the placenta with the venous blood, and is rarely retained in the placental lesions. After a small amount of drug retained in the placenta is internalized by the diseased cells, the shell cannot play an antioxidant function in the cells. The antioxidant treatment MXRA5 plasmid and the residual GSH in the shell are distributed with the drug and enter the diseased cells with low efficiency. Compared with the embodiment, the blood pressure is significantly higher and close to the untreated disease model; the fetal weight is significantly lower and close to the untreated disease model; the number of piglets per litter is significantly higher and close to the untreated disease model.

[0098] Comparative Example 2 lacks an outer shell that can cover up the strong positive charge of the inner core. In the process of blood circulation before entering the lesion, the obvious positive charge on the surface of the inner core of the drug PLys-PPhe carrier stimulates the reticuloendothelial system mainly in the liver. Furthermore, the drug is significantly intercepted and engulfed by the reticuloendothelial system, the blood drug concentration is reduced, and very little drug enters the placenta. The antioxidant treatment plasmid and the residual GSH in the outer shell are distributed with the drug and enter the placenta inefficiently, resulting in extremely low efficiency in entering the diseased cells. Compared with the embodiment, the blood pressure is significantly higher and close to the untreated disease model; the fetal weight is significantly lower and close to the untreated disease model; the number of offspring per litter is significantly higher and close to the untreated disease model.

[0099] The particle size of the delivery system of Comparative Example 3 is too large, the efficiency of the antioxidant therapeutic plasmid and the residual GSH in the shell entering the placenta along with the drug distribution is low, the drug concentration in the placenta is reduced, and the efficiency of the drug entering the diseased cells is extremely low. Compared with the embodiments, the blood pressure is significantly higher and close to the untreated disease model; the fetal weight is significantly lower and close to the untreated disease model; the number of piglets per litter is significantly higher and close to the untreated disease model.

[0100] The particle size of comparative example 4 is too small, the antioxidant treatment plasmid and the residual GSH in the shell are distributed with the drug, and the drug entering the placenta flows out of the placenta in large quantities, and it is impossible to achieve effective retention in the placenta, and the drug concentration in the placenta is extremely low. Therefore, the efficiency of the drug entering the diseased cells is low. Compared with the embodiment, the blood pressure is significantly higher and close to the untreated disease model; the fetal weight is significantly lower and close to the untreated disease model; the number of litters per litter is significantly higher and close to the untreated disease model.

[0101] 3. Toxicity evaluation of drugs in animal models

[0102] 72 hours after the injection of the drug, the mice in the normal control group were blooded from the tail vein to detect liver function indicators alanine transaminase (ALT), total bilirubin (TBil) and renal function indicators blood urea nitrogen (BUN) and serum creatinine (sCr). The detection instrument was Hitachi 7600 automatic biochemical analyzer, and the test results are shown in Table 4.

[0103] Table 4 Toxicity evaluation results

[0104]

[0105]

[0106] From the above results, it can be seen that the nanocarriers prepared by the present invention have less drug retention in the liver and lower liver toxicity. At the same time, these drugs achieve efficient distribution similar to lesion targeting in the placenta, the blood drug concentration is reduced, the kidneys do not produce obvious toxic reactions, and the renal function does not change significantly.

Claims

1. An essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapy, characterized in that: The carrier is a micelle formed by self-assembly of a multi-block polymer in water, wherein the multi-block polymer is mPEG-GSH-PLys-PPhe, wherein the hydrophilic shell is mPEG-GSH, the core is PLys-PPhe encapsulating drugs or therapeutic genes, and the shell and the core are connected via an amide bond.

2. The essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 1, characterized in that: The structural formula of the multi-block polymer is: Among them, x=45-80, y=40-60, z=20-30.

3. The essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 1, characterized in that: The average particle size of the carrier is 80-120 nm.

4. The essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 1, characterized in that: The therapeutic gene is a gene that plays an antioxidant role in cells, preferably MXRA5.

5. The method for preparing an essential amino acid carrier having microenvironment redox response and diseased cell antioxidant therapeutic function according to any one of claims 1 to 4, characterized in that: The steps include: (1) Synthesis of mPEG-ss-GSH: The monomethoxy-polyethylene glycol-thiol mPEG-SH was oxidized with glutathione in water at 20-25°C for 12-24 hours, and then dialyzed to obtain mPEG-ss-GSH; (2) Synthesis of mPEG-GSH-PZLL: Dissolve N6-benzyloxycarbonyllysine-L-carbonyl anhydride Lys-NCA and mPEG-ss-GSH obtained in step (1) in DMF, stir and react in an oil bath at 30-35°C for 48-72 h. After the reaction is completed, precipitate the reactants with excess ether to obtain mPEG-GSH-PZLL; (3) Synthesis of mPEG-GSH-PZLL-PPhe: Dissolve the mPEG-GSH-PZLL and phenylalanine N-carbonyl carboxylic anhydride Phe-NCA synthesized in step (2) in DMF, stir and react in an oil bath at 30-35°C for 24-48 hours. After the reaction is completed, precipitate the reactants with excess ether to obtain mPEG-GSH-PZLL-PPhe. (4) Deprotection of mPEG-GSH-PZLL-PPhe Dissolve the mPEG-GSH-PZLL-PPhe obtained in step (3) in trifluoroacetic acid, then introduce hydrogen bromide gas, and bubble the reaction for 20-40 min. Continue stirring in an ice bath for 10-15 h. The reactant is precipitated with excess ether to obtain deprotected mPEG-GSH-PZLL-PPhe. (5) Preparation of nanocarriers: The deprotected mPEG-GSH-PLys-PPhe is dissolved in chloroform, and then the mixed solution is added dropwise into PBS in an ice bath under ultrasound, the chloroform is removed, and the mPEG-GSH-PLys-PPhe nanoparticle solution is obtained by filtration; the diluted solution of the drug or therapeutic gene is mixed with the mPEG-GSH-PLys-PPhe nanoparticle solution, the mixture is mixed by blowing and allowed to stand, and then dialyzed to obtain the essential amino acid carrier for the microenvironment redox response and the antioxidant therapeutic function of the diseased cells.

6. The method for preparing the essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 5, characterized in that: In step (1), the molar ratio of mPEG-SH to glutathione is 1:1; and the molecular cutoff of the dialysis bag used for dialysis is 0.5-1 kDa.

7. The method for preparing the essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 5, characterized in that: In step (2), the molar ratio of the N6-benzyloxycarbonyllysine-L-carbonyl anhydride Lys-NCA to mPEG-ss-GSH is 40:1-60:

1.

8. The method for preparing the essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 5, characterized in that: In step (3), the molar ratio of the phenylalanine N-carbonyl carboxylic anhydride Phe-NCA to mPEG-GSH-PZLL is 20:1-30:

1.

9. The method for preparing the essential amino acid carrier for microenvironment redox response and diseased cell antioxidant therapeutic function according to claim 5, characterized in that: In step (5), after removing the chloroform, the solution is filtered through an aqueous filter with a pore size of 0.4-0.6 μm to remove large aggregates, and then dialyzed in pure water using a dialysis bag with a molecular cutoff of 5-14 kDa to remove polymers that have not formed particles. Finally, the mPEG-GSH-PLys-PPhe nanoparticle solution is concentrated using an ultrafiltration tube with a molecular cutoff of 100-200 kDa, washed with pure water, and filtered through an aqueous filter with a pore size of 0.1-0.22 μm to obtain an mPEG-GSH-PLys-PPhe nanoparticle solution.

10. Use of the essential amino acid carrier with microenvironment redox response and diseased cell antioxidant therapeutic function according to any one of claims 1 to 4 in the preparation of a drug for treating placental oxidative stress-related diseases such as preeclampsia.

Citation Information

Cited By

  • Essential amino acid vector having functions of micro-environment redox response and Anti-oxidation treatment on diseased cells, preparation method therefor, and use thereof

    WO2026031545A1